Alan Dal Pra

List of Publications by Citations

66 papers	1,801 citations	18 h-index	42 g-index
77 ext. papers	2,266 ext. citations	5.4 avg, IF	4.34 L-index

#	Paper	IF	Citations
66	Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*, **2017**, 541, 359-364	50.4	320
65	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
64	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology, The*, **2014**, 15, 1521-1532	21.7	218
63	Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. *Clinical Cancer Research*, **2013**, 19, 6741-50	12.9	213
62	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. *European Urology*, **2017**, 72, 665-674	10.2	98
61	Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. *Journal of Translational Medicine*, **2018**, 16, 223	8.5	43
60	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 982-995	4	41
59	Objective consensus from decision trees. *Radiation Oncology*, **2014**, 9, 270	4.2	34
58	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. *Clinical Cancer Research*, **2013**, 19, 5202-9	12.9	34
57	Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. *British Journal of Radiology*, **2016**, 89, 20160217	3.4	33
56	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. *Nature Reviews Urology*, **2015**, 12, 193-204	5.5	30
55	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. *European Urology*, **2021**, 79, 374-383	10.2	28
54	Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. *Advances in Experimental Medicine and Biology*, **2014**, 772, 189-204	3.6	26
53	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. *Translational Andrology and Urology*, **2018**, 7, 445-458	2.3	23
52	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. *Radiation Oncology*, **2018**, 13, 216	4.2	21
51	Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e455-62	4	19
50	Prostate cancer radiation therapy: A physicianꞌs perspective. *Physica Medica*, **2016**, 32, 438-45	2.7	19

49	Segmentation of prostate and prostate zones using deep learning : A multi-MRI vendor analysis. *Strahlentherapie Und Onkologie*, **2020**, 196, 932-942	4.3	18
48	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review. *Radiotherapy and Oncology*, **2016**, 119, 185-93	5.3	18
47	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. *Frontiers in Oncology*, **2016**, 6, 24	5.3	17
46	T1-2 glottic cancer treated with radiotherapy and/or surgery. *Strahlentherapie Und Onkologie*, **2017**, 193, 995-1004	4.3	16
45	Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. *Strahlentherapie Und Onkologie*, **2015**, 191, 778-86	4.3	16
44	Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. *Cancer Treatment Reviews*, **2016**, 46, 35-41	14.4	15
43	Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. *Radiotherapy and Oncology*, **2011**, 101, 486-9	5.3	14
42	Urethral strictures after radiation therapy for prostate cancer. *Investigative and Clinical Urology*, **2016**, 57, 309-15	1.9	13
41	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. *Radiotherapy and Oncology*, **2018**, 126, 257-262	5.3	13
40	Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice. *Strahlentherapie Und Onkologie*, **2018**, 194, 9-16	4.3	11
39	Radiation therapy and androgen deprivation in the management of high risk prostate cancer. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2011**, 37, 161-75; discussion 176-9	2	11
38	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. *European Urology Focus*, **2015**, 1, 173-184	5.1	10
37	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. *Otolaryngology - Head and Neck Surgery*, **2016**, 154, 300-8	5.5	9
36	Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. *Frontiers in Oncology*, **2019**, 9, 12	5.3	9
35	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. *Radiation Oncology*, **2016**, 11, 48	4.2	9
34	An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 821-829	4	9
33	The role of radiomics in prostate cancer radiotherapy. *Strahlentherapie Und Onkologie*, **2020**, 196, 900-912	4.3	9
32	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. *Radiation Oncology*, **2019**, 14, 177	4.2	8

31	Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. *British Journal of Radiology*, **2020**, 93, 20200028	3.4	7
30	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. *Physica Medica*, **2020**, 77, 154-159	2.7	6
29	Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. *Radiation Oncology*, **2015**, 10, 20	4.2	5
28	Contemporary role of postoperative radiotherapy for prostate cancer. *Translational Andrology and Urology*, **2018**, 7, 399-413	2.3	5
27	Prognostic utility of cell cycle progession score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 237-40	4	4
26	Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. *Thoracic Cancer*, **2020**, 11, 3139-3144	3.2	4
25	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. *Medical Physics*, **2021**, 48, 2386-2399	4.4	4
24	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. *Journal of Urology*, **2021**, 205, 1344-1351	2.5	4
23	Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727). *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1319	4	3
22	The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. *Critical Reviews in Oncology/Hematology*, **2021**, 168, 103497	7	3
21	Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. *Frontiers in Oncology*, **2020**, 10, 617302	3.3	3
20	Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. *Radiation Oncology*, **2017**, 12, 102	4.2	2
19	Does transperitoneal minimally invasive radical prostatectomy increase the amount of small bowel receiving salvage radiation?. *Canadian Urological Association Journal*, **2013**, 7, 444-8	1.2	2
18	Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?. *Journal of Clinical Oncology*, **2019**, 37, e20720-e20720	2.2	2
17	Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. *Physica Medica*, **2021**, 81, 77-85	2.7	2
16	Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7. *European Urology*, **2018**, 73, e34-e35	10.2	1
15	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. *Journal of Clinical Oncology*, **2016**, 34, e80-3	2.2	1
14	Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?. *Journal of Clinical Oncology*, **2020**, 38, 9579-9579	2.2	1

13	Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy. *International Journal of Particle Therapy*, **2021**, 8, 62-72	1.5	1
12	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. *Journal of Clinical Oncology*, **2018**, 36, TPS157-TPS157	2.2	0
11	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. *Journal of Clinical Oncology*, **2021**, 39, 5010-5010	2.2	0
10	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). *Cancer Genetics* , **2021**, 258-259, 61-68	2.3	0
9	Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265-7. *European Urology*, **2019**, 76, e148-e149	10.2	
8	Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. *Nature Reviews Urology*, **2020**, 17, 489-490	5.5	
7	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. *Advances in Radiation Oncology*, **2022**, 7, 100832	3.3	
6	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 117-117	2.2	
5	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. *Journal of Clinical Oncology*, **2016**, 34, 96-96	2.2	
4	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. *Journal of Clinical Oncology*, **2016**, 34, 49-49	2.2	
3	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5051-5051	2.2	
2	Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol 2020;78:661-9. *European Urology*, **2020**, 78, e221-e222	10.2	
1	Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification?. *European Urology*, **2016**, 69, e74-e75	10.2	